Thyroid dysfunction during PD-1 inhibitor treatment in patients with cancer: Incidence and association with progression-free survival

The use of programmed cell death-1 (PD-1) inhibitors has recently been approved in China. As a consequence, the identification of relevant prognostic markers that can assess the efficacy of these compounds is required. Therefore, the present study aimed to explore the incidence of thyroid dysfunctio...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yanfei, Wang, Zhi, Bai, Hongxia, Gao, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353241/
https://www.ncbi.nlm.nih.gov/pubmed/35949599
http://dx.doi.org/10.3892/ol.2022.13429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353241/
https://www.ncbi.nlm.nih.gov/pubmed/35949599
http://dx.doi.org/10.3892/ol.2022.13429

Ejemplares similares